

=> D HIS

(FILE 'HOME' ENTERED AT 17:42:26 ON 28 JAN 2000)

FILE 'HCAPLUS' ENTERED AT 17:42:36 ON 28 JAN 2000

L1 207 S LAL P?/AU  
 L2 94 S GUEGLER K?/AU  
 L3 165 S CORLEY N?/AU  
 L4 29 S L1 AND L2 AND L3  
 L5 2 S L4 AND (PROSTATE? OR PGAMP?)  
 L6 315 S L1-3  
 L7 21 S L6 AND (PROSTATE? OR PGAMP?)  
 L8 19 S L7 NOT L5

FILE 'MEDLINE, USPATFULL' ENTERED AT 17:46:52 ON 28 JAN 2000

L9 152 S LAL P?/AU  
 L10 57 S GUEGLER K?/AU  
 L11 125 S CORLEY N?/AU  
 L12 10 S L1 AND L2 AND L3  
 L13 2 S L12 NOT L7  
 L14 2 DUP REM L13 (0 DUPLICATES REMOVED)  
 L15 241 S L9-11  
 L16 152 S L15 AND (PROSTATE? OR PGAMP?)  
 L17 0 S L16 NOT L7  
 L18 144 S L16 NOT L12  
 L19 144 DUP REM L18 (0 DUPLICATES REMOVED)  
 L20 0 S L15 (L) (PROSTATE? OR PGAMP?)  
 L21 0 S L15 AND PGAMP?  
 L22 20 S PROSTATE(3A)MEMBRANE(3A)PROTEIN#  
 L23 0 S L22 AND L19

=&gt; D BIB ABS L5

L5 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1999:764064 HCAPLUS  
 DN 132:10145  
 TI Human **prostate** growth-associated membrane proteins **PGAMP**  
**-1** and **PGAMP-2**, polynucleotides identifying and encoding  
**PGAMP-1** and **PGAMP-2**, use of these for treatment and/or  
 prevention of neoplastic and reproductive disorders  
 IN **Lal, Preeti; Guegler, Karl J.; Corley, Neil C.**  
 PA Incyte Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 72 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9961469	A2	19991202	WO 1999-US10888	19990517
	W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		

PRAI US 1998-83521 19980522

AB The invention provides two human **prostate** growth-assocd. membrane proteins (**PGAMP-1** and **PGAMP-2**), and polynucleotides which identify and encode **PGAMP-1** and **PGAMP-2**. The invention also provides expression vectors contg. the polynucleotides encoding **PGAMP-1** or **PGAMP-2**, and host cells transformed with said expression vectors for the recombinant prodn. of **PGAMP-1** or **PGAMP-2**. The invention further provides antagonists and/or agonists of **PGAMP-1** or **PGAMP-2**, and use of the antagonists in treating or preventing a neoplastic or reproductive disorder. Finally, the invention presents the use of polymerase chain reaction (PCR) followed by nucleic acid hybridization to identify nucleic acids encoding **PGAMP-1** or **PGAMP-2** in a biol. sample. The cDNA sequences as well as the amino acid sequences of human **PGAMP-1** and **PGAMP-2** are provided. **PGAMP-1** was shown to have chem. and structural similarity with rat heat-stable antigen, while **PGAMP-2** was shown to have similarity with a fragment of the mouse apoptosis-assocd. tyrosine kinase and human **prostate-specific antigen (PSA)**.

=&gt; D BIB ABS L5 2

L5 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1999:595376 HCAPLUS  
 DN 131:210089  
 TI Cloning of cDNA sequences encoding human membrane spanning proteins  
 IN Tang, Y. Tom; Bandman, Olga; Lal, Preeti; Hillman, Jennifer L.;  
 Yue, Henry; Corley, Neil C.; Guegler, Karl J.; Kaser,  
 Matthew R.; Baughn, Mariah R.; Shah, Purvi  
 PA Incyte Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 81 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9946380	A2	19990916	WO 1999-US5073	19990309
	WO 9946380	A3	19991216		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9930729	A1	19990927	AU 1999-30729	19990309
PRAI	US 1998-39064		19980313		
	WO 1999-US5073		19990309		
AB	The invention provides a human membrane spanning proteins (MSPs) and polynucleotides which identify and encode MSPs. Nucleic acids encoding 6 MSPs were first identified in Incyte clones from synovial membrane tissue, brain, fetal colon, corpus callosum, <b>prostate</b> , and colon cDNA libraries using a computer search for amino acid sequence alignments; consensus sequences were derived from extended or overlapping clones. Deduced amino acid sequences, homologies, and Northern blot tissue expression specificities are provided. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders assocd. with expression of MSPs.				

=&gt; D BIB ABS L8

L8 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1999:808581 HCAPLUS  
 DN 132:45839  
 TI Cloning and cDNA sequence of a human S1-5 ECMP-like protein (SELP) and its diagnostic and therapeutic uses  
 IN Yue, Henry; Guegler, Karl J.; Shah, Purvi  
 PA Incyte Pharmaceuticals, Inc., USA  
 SO U.S., 29 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6004753	A	19991221	US 1997-980514	19971201
AB	The invention provides a human S1-5 ECMP-like protein (SELP) and polynucleotides which identify and encode SELP. SELP nucleic acid was first identified in Incyte Clone 2786449 from a breast cDNA library. SELP is 443 amino acids in length and comprises potential glycosylation sites, casein kinase II and protein kinase C phosphorylation sites, potential signal peptide, and EGF-like domains. SELP and human S1-5 gene product share 49% identity. The expression of SELP was found in heart, lung, brain, spinal cord, thyroid, breast, <b>prostate</b> , uterus, ovary, penis, gastrointestinal, and bladder tissue, and in smooth muscle, hematopoietic, and rheumatoid tissues. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing immunol. and neoplastic disorders assocd. with expression of SELP.				

=&gt; D BIB ABS L8 2-19

L8 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1999:622230 HCAPLUS  
 DN 131:238832  
 TI Cloning and cDNA sequences for human electron transport proteins NHETP  
 IN Hillman, Jennifer L.; Bandman, Olga; Lal, Preeti; Corley, Neil C.  
 PA Incyte Pharmaceuticals, Inc., USA  
 SO U.S., 45 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5958746	A	19990928	US 1997-946528	19971007
AB	The invention provides human electron transport proteins (NHETP) and polynucleotides which identify and encode NHETP. Nucleic acids encoding NHETP-1, -2, and -3 were first identified in Incyte clones from <b>prostate</b> tissue, pancreatic tumor, and pancreatic islet cell cDNA libraries, resp., using a computer search for amino acid sequence alignments; consensus sequences were derived from overlapping and/or extended nucleic acid sequences. The 3 proteins are 305, 171, and 128 amino acid residues in length with chem. and structural homol. with cytochrome b5 reductase, human cytochrome oxidase subunit 4, and bovine NADH dehydrogenase subunit B14, resp. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating or preventing disorders assocd. with expression of NHETP.				

L8 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1999:566173 HCAPLUS  
 DN 131:166249  
 TI Cloning of three cDNA sequences encoding human channel-related molecules  
 HCRM

IN Bandman, Olga; Yue, Henry; Lal, Preeti; Corley, Neil C.  
; Au-Young, Janice; Tang, Y. Tom; Baughn, Mariah R.

PA Incyte Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9943807	A2	19990902	WO 1999-US2739	19990208
	WO 9943807	A3	19991216		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9926649	A1	19990915	AU 1999-26649	19990208
PRAI	US 1998-30747		19980225		
	WO 1999-US2739		19990208		
AB	The invention provides human channel-related mols. (HCRM) and polynucleotides which identify and encode HCRM. Nucleic acids encoding HCRMs were first identified in Incyte clones for <b>prostate</b> tumor, breast tumor, and ovarian tumor cDNA libraries using a computer search for amino acid sequence alignments; consensus sequences were derived from overlapping and/or extended nucleic acid sequences. HCRM-1, HCRM-2, and HCRM-2 are 216, 178, and 229 amino acids in length, resp., with chem. and structural homologies to known transport channel proteins. This invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders assocd. with expression of HCRM.				

L8 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2000 ACS

AN 1999:566171 HCAPLUS

DN 131:167099

TI Cloning of cDNA encoding human protein kinase C inhibitor

IN Yue, Henry; Hillman, Jennifer L.; Guegler, Karl J.; Corley, Neil C.

PA Incyte Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9943805	A1	19990902	WO 1999-US2634	19990208
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9925912	A1	19990915	AU 1999-25912	19990208
PRAI	US 1998-28328		19980224		
	WO 1999-US2634		19990208		
AB	The invention provides a human C-kinase inhibitor (HPKCI) and polynucleotides which identify and encode HPKCI. Nucleic acids encoding HPKCI were first identified in Incyte clone 2922091 from an ileum tissue cDNA library using a computer search for amino acid sequence alignments; a consensus sequence was derived from overlapping and/or extended nucleic acid sequences. HPKCI is 182 amino acids in length with chem. and structural homol. with PKCI-1 from human and CPKCI from Caenorhabditis elegans. Northern anal. shows the expression of this sequence in various libraries, at least 50% of which are immortalized or cancerous (esp. breast				

SEARCHED BY SUSAN HANLEY 305-4053

and **prostate** tumors) and at least 22% of which involve immune response. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders assocd. with expression of HPKCI.

L8 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2000 ACS

AN 1999:549375 HCAPLUS

DN 131:166236

TI Cloning of cDNA sequence encoding human CAF1-related protein

IN Hillman, Jennifer L.; Corley, Neil C.; Yue, Henry

PA Incyte Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9942579	A2	19990826	WO 1999-US2463	19990205
WO 9942579	A3	19991014		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6013450	A	20000111	US 1998-27137	19980220
AU 9926580	A1	19990906	AU 1999-26580	19990205
PRAI US 1998-27137		19980220		
WO 1999-US2463		19990205		

AB The invention provides a human CAF1-related protein (CAFRP) and polynucleotides which identify and encode CAFRP. Nucleic acids encoding CAFRP were first identified in Incyte clone 2229466 from a **prostate** cDNA library using a computer search for amino acid sequence alignments; a consensus sequence was derived from overlapping and/or extended nucleic acid sequences. CAFRP is 292 amino acids in length and has a potential N-glycosylation site, 6 potential casein kinase II phosphorylation sites, a potential protein kinase C phosphorylation site, and a potential tyrosine phosphorylation site, and has 76% amino acid identity with mouse CAF1 protein. Northern anal. shows the expression of CAFRP in various libraries, at least 48% of which are immortalized or cancerous, at least 27% of which involve immune response, and at least 14% of which involve fetal/proliferating cells. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for the diagnosis, treatment, or prevention of disorders assocd. with cell proliferation and inflammation.

L8 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2000 ACS

AN 1999:529268 HCAPLUS

DN 131:154491

TI Cloning and cDNA sequence encoding human **prostate**-associated serine protease

IN Tang, Y. Tom; Corley, Neil C.; Guegler, Karl J.

PA Incyte Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9941387	A2	19990819	WO 1999-US2571	19990205
WO 9941387	A3	19990930		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,			

SEARCHED BY SUSAN HANLEY 305-4053

NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9925894 A1 19990830 AU 1999-25894 19990205  
 PRAI US 1998-25059 19980217  
 WO 1999-US2571 19990205

AB The invention provides a human **prostate**-assocd. serine protease (PRASP) and polynucleotides which identify and encode PRASP. Nucleic acids encoding PRASP were first identified in Incyte clone 2723646 from a lung tumor cDNA library using a computer search for amino acid sequence alignments; a consensus sequence was derived from overlapping and/or extended nucleic acid sequences. PRASP is 282 amino acids in length and has 4 potential N-glycosylation sites, 3 potential casein kinase II phosphorylation sites, 5 potential protein kinase C phosphorylation sites, potential signal peptide and activation peptide sequences, and 2 serine protease trypsin family active site motifs, with chem. and structural homol. with mouse neuropsin and human PSA. Northern anal. shows the expression of this sequence in various libraries, .gtoreq.81% of which are assocd. with cancer. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders assocd. with expression of PRASP.

L8 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1999:468022 HCAPLUS  
 DN 131:99271  
 TI Cloning and cDNA sequence of human short-chain dehydrogenase  
 IN **Lal, Preeti; Corley, Neil C.**  
 PA Incyte Pharmaceuticals, Inc., USA  
 SO U.S., 27 pp.  
 CODEN: USXXAM

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5928923	A	19990727	US 1998-19216	19980205
AB	The invention provides a human short-chain dehydrogenase (HSCD) and polynucleotides which identify and encode HSCD. Nucleic acids encoding HSCD were first identified in Incyte clone 365351 from a <b>prostate</b> cDNA library using a computer search for amino acid sequence alignments; a consensus sequence was derived from overlapping and/or extended nucleic acid sequences. HSCD is 313 amino acids in length and has 4 potential casein kinase II phosphorylation sites, one potential glycosaminoglycan attachment site, one potential microbodies C-terminal targeting signal site, 4 potential N-myristoylation sites, and 5 potential protein kinase C phosphorylation sites, as well as chem. and structural homol. with short-chain acyl-CoA dehydrogenase. Northern anal. shows the expression of this sequence in various libraries, at least 50% of which are immortalized or cancerous and .gtoreq.27% of which involve the immune response. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders assocd. with expression of HSCD.				

L8 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1999:412634 HCAPLUS  
 DN 131:54792  
 TI New human SH3-containing proteins and cDNAs and their therapeutic use  
 IN Bandman, Olga; Guegler, Karl J.; **Lal, Preeti**  
 PA Incyte Pharmaceuticals, Inc., USA  
 SO U.S., 32 pp.  
 CODEN: USXXAM

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

SEARCHED BY SUSAN HANLEY 305-4053

PI US 5916753 A 19990629 US 1997-970133 19971113  
 AB The invention is based on the discovery of two new human SH3-contg. proteins (HS3C), the polynucleotides encoding HS3C, and the use of these compns. for the diagnosis, prevention, or treatment of cancer and immune and developmental disorders. Nucleic acids encoding the HS3C-1 of the present invention were first identified in Incyte Clone 865744 from the brain tumor cDNA library (BRAITUT03) and the HS3C-2 in Incyte Clone 1816529 from the normal **prostate** tissue cDNA library (PROSNOT20) using a computer search for amino acid sequence alignments. Expression vectors, host cells, antibodies, agonists, and antagonists are also provided. Methods for treating or preventing disorders assocd. with expression of HS3C are described.

L8 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1999:388282 HCAPLUS  
 DN 131:40565  
 TI Cloning and cDNA sequence encoding human G-protein coupled receptors associated with immune response  
 IN Lal, Preeti; Bandman, Olga; Hillman, Jennifer L.; Yue, Henry  
 PA Incyte Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9929849	A1	19990617	WO 1998-US25565	19981202
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9916201	A1	19990628	AU 1999-16201	19981202
US 1997-988876		19971211		
WO 1998-US25565		19981202		
AB The invention provides two human G-protein coupled receptors assocd. with immune response (GRIR) and polynucleotides which identify and encode GRIR. Nucleic acids encoding GRIR-1 and GRIR-2 were first identified in Incyte clones 364702 and 1650519 from a <b>prostate</b> cDNA library using a computer search for amino acid sequence alignments; consensus sequences were derived from overlapping or extended clones. GRIR-1 is 326 amino acids in length, has two potential N-glycosylation sites and five potential phosphorylation sites, and has chem. and structural homol. with canine rat, and human olfactory receptors. GRIR-2 is 358 amino acids in length with five potential N-glycosylation sites and nine potential phosphorylation sites, and has chem. and structural homol. to human KIAA0001 and rat VTR 15-20. Northern anal. shows the expression of these sequences in gastrointestinal reproductive, and muscle libraries, with a large no. of these libraries assocd. with neoplastic disorders. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders assocd. with expression of GRIR.				

L8 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1999:113812 HCAPLUS  
 DN 130:178376  
 TI Cloning and cDNA sequence of human annexin-binding protein NABP-1  
 IN Hillman, Jennifer L.; Corley, Neil C.; Shah, Purvi  
 PA Incyte Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

SEARCHED BY SUSAN HANLEY 305-4053

PI WO 9906560 A1 19990211 WO 1998-US15599 19980728  
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
US 5932712 A 19990803 US 1997-903801 19970731  
AU 9885964 A1 19990222 AU 1998-85964 19980728  
PRAI US 1997-903801 19970731  
WO 1998-US15599 19980728  
AB The invention provides a human annexin binding protein (NABP-1) and polynucleotides which identify and encode NABP-1. Nucleic acids encoding NABP-1 were first identified in Incyte clone 2272281 from a normal **prostate** cDNA library using a computer search for amino acid sequence alignments; a consensus sequence was derived from overlapping and/or extended nucleic acid sequences. NABP-1 is 290 amino acids in length and has 2 potential N-linked glycosylation sites, numerous phosphorylation sites, and chem. and structural homol. with rat annexin V-binding protein. Northern anal. shows the expression of NABP-1 in various libraries, .gtoreq.35% of which are immortalized or cancerous, .gtoreq.20% of which involve inflammation and the immune response, and 14% of which involve the brain and neural tissues. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders assocd. with expression of NABP-1.

L8 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2000 ACS  
AN 1999:34928 HCAPLUS  
DN 130:106040  
TI Cloning and cDNA sequence of a human transmembrane protein HT4P  
IN Hillman, Jennifer L.; Corley, Neil C.; Shah, Purvi  
PA Incyte Pharmaceuticals, Inc., USA  
SO PCT Int. Appl., 57 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9900408	A2	19990107	WO 1998-US9878	19980513
WO 9900408	A3	19990415		
W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9875723	A1	19990119	AU 1998-75723	19980514
PRAI US 1997-855519		19970513		
WO 1998-US9878		19980513		
AB				
The present invention provides a human transmembrane 4 protein (HT4P) and polynucleotides which encode HT4P. Nucleic acids encoding human HT4P were first identified in Incyte clone 2279874 from a normal <b>prostate</b> cDNA library through a computer search for amino acid sequence alignments; a consensus sequence was derived from overlapping and/or extended nucleic acid sequences. HT4P is 204 amino acids in length and has potential N-linked glycosylation sites, a potential casein kinase II phosphorylation site, and potential protein kinase C phosphorylation site, as well as chem. and structural homol. with human and pig SAS proteins. Northern anal. shows the expression of HT4P in various libraries, 41% of which are assocd. with cancer and immortalized cell lines, 33% of which are assocd. with smooth muscle and the sympathetic nervous system, and 18% of which are assocd. with the brain and neural tissue. The invention also provides expression vectors, host cells, agonists, antisense mols., antibodies, or antagonists. The invention also provides methods for treating disorders assocd. with expression of HT4P.				

AN 1998:795131 HCAPLUS  
 DN 130:48322  
 TI sequence and clinical diagnosis and therapeutic applications for new human  
 dpi homolog  
 IN Bandman, Olga; **Guegler, Karl J.**; Shah, Purvi; Petithory, Joanne  
 R.; **Corley, Neil C.**  
 PA Incyte Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 62 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9854321	A1	19981203	WO 1998-US10799	19980527
	W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5958725	A	19990928	US 1997-865336	19970529
	AU 9876020	A1	19981230	AU 1998-76020	19980527
PRAI	US 1997-865336		19970529		
	WO 1998-US10799		19980527		
AB	The invention provides a human DPl homolog (DPlh) and polynucleotides which identify and encode DPlh. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders assocd. with expression of DPlh.				

L8 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2000 ACS

AN 1998:774154 HCAPLUS  
 DN 130:21382  
 TI Cloning and cDNA sequence of human vesicle transport-associated proteins  
 IN Hillman, Jennifer L.; **Lal, Preeti**; Shah, Purvi; **Corley, Neil C.**  
 PA Incyte Pharmaceuticals Inc., USA  
 SO U.S., 48 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5840539	A	19981124	US 1997-948616	19971010
	WO 9919482	A2	19990422	WO 1998-US21314	19981009
	WO 9919482	A3	19990708		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9897944	A1	19990503	AU 1998-97944	19981009
	US 5981226	A	19991109	US 1998-193510	19981117
PRAI	US 1997-948616		19971010		
	WO 1998-US21314		19981009		
AB	The invention provides 3 human vesicle transport-assocd. proteins (VTAP) and polynucleotides which identify and encode VTAP. Nucleic acids encoding VTAP-1, -2, and -3 were first identified in Incyte clones from <b>prostate</b> tumor, lung tumor, and epidermal keratinocyte cDNA libraries, resp., using a computer search for amino acid sequence alignments; consensus sequences were derived from overlapping and/or extended nucleic acid sequences. The proteins are 111, 307, and 210 amino acids in length and share chem. and structural homol. with known transport proteins. Northern anal. shows the expression of these sequence in various libraries, esp. those which are immortalized or cancerous. The invention also provides expression vectors, host cells, agonists,				

SEARCHED BY SUSAN HANLEY 305-4053

antibodies and antagonists. The invention also provides methods for treating disorders assocd. with expression of VTAP.

L8 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1998:761964 HCAPLUS  
 DN 130:21370  
 TI Cloning and cDNA sequence of human 3-hydroxyisobutyryl-Coenzyme A hydrolase  
 IN Bandman, Olga; Guegler, Karl J.; Corley, Neil C.; Shah, Purvi  
 PA Incyte Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9851782	A2	19981119	WO 1998-US10150	19980518
	WO 9851782	A3	19990204		
	W:	AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 5849498	A	19981215	US 1997-858052	19970516
	AU 9875778	A1	19981208	AU 1998-75778	19980518
PRAI	US 1997-858052		19970516		
	WO 1998-US10150		19980518		
AB	The present invention provides a human 3-hydroxyisobutyryl-CoA hydrolase (HIBCOH) and polynucleotides which identify and encode HIBCOH. Nucleic acids encoding human HIBCOH were first identified in Incyte clone 1187 from a U937 monocyte-like cell line cDNA library through a computer search for amino acid sequence alignments; a consensus sequence was derived from overlapping and/or extended nucleic acid sequences. HIBCOH is 381 amino acids in length and has chem. and structural homol. with a 3-hydroxyisobutyryl-CoA hydrolase from human and a putative enoyl-CoA hydratase from <i>Caenorhabditis elegans</i> . Northern anal. found HIBCOH in kidney, adrenal gland, pituitary, brain, small intestine, colon, pancreas, heart, liver, lung, macrophages, monocytes, skeletal and smooth muscle, breast, ovary, uterus, and <b>prostate</b> . The invention also provides expression vectors, host cells, and antibodies. The invention also provides methods for the prevention and treatment of diseases assocd. with expression of HIBCOH, as well as diagnostic assays.				

L8 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1998:734984 HCAPLUS  
 DN 129:340561  
 TI Cloning and cDNA sequence of human clathrin-associated protein  
 IN Bandman, Olga; Corley, Neil C.; Shah, Purvi  
 PA Incyte Pharmaceuticals, Inc., USA  
 SO U.S., 25 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5834242	A	19981110	US 1997-850119	19970501
AB	The present invention provides a new human clathrin-assocd. protein (CLAPH) and polynucleotides which identify and encode CLAPH. Nucleic acids encoding human CLAPH were first identified in Incyte clone 790666 from a <b>prostate</b> tumor tissue cDNA library through a computer-generated search for amino acid sequence alignments; a consensus sequence was derived from overlapping and/or extended nucleic acid sequences. CLAPH is 193 amino acids in length and has chem. and structural homol. with CLAPS3 from human, APL9 from mouse, and APL7 from rat. Northern anal. indicates the expression of CLAPH in cells and tissues involved in secretion or absorption, cells and tissues assocd. with the immune response, and tumor-assocd. tissues. The invention also				

SEARCHED BY SUSAN HANLEY 305-4053

provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases assocd. with expression of CLAPH, as well as diagnostic assays.

L8 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1998:728557 HCAPLUS  
 DN 130:1185  
 TI Cloning and cDNA sequence of a human retinoid-binding protein  
 IN Bandman, Olga; Lal, Preeti; Petithory, Joanne R.  
 PA Incyte Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 58 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9849301	A1	19981105	WO 1998-US8130	19980427
W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5955305	A	19990921	US 1997-847724	19970428
AU 9871487	A1	19981124	AU 1998-71487	19980427
PRAI US 1997-847724		19970428		
WO 1998-US8130		19980427		

AB The present invention provides a human retinoid binding protein (Hu-RBP) and polynucleotides which identify and encode Hu-RBP. Nucleic acids encoding human Hu-RBP were first identified in Incyte clone 879706 from a Graves' disease (hyperthyroidism) thyroid tissue cDNA library through a computer-generated search for amino acid sequence alignments; a consensus sequence was derived from overlapping and/or extended nucleic acid sequences. Hu-RBP is 134 amino acids in length and has chem. and structural homol. with CRBP II from pig, CRBP from rat, CRBP II from human, and CRBP from human. Northern anal. shows the expression of Hu-RBP in neuronal and secretory tissues, including brain, spinal cord/dorsal root ganglion, thyroid, ovary, breast, **prostate**, stomach, and lung. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases assocd. with expression of Hu-RBP, as well as diagnostic assays.

L8 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1998:719174 HCAPLUS  
 DN 129:326980  
 TI Cloning and cDNA sequence of human translocation-associated protein Gp25L-H  
 IN Hillman, Jennifer L.; Corley, Neil C.; Goli, Surya K.  
 PA Incyte Pharmaceuticals, Inc, USA  
 SO U.S., 28 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5831052	A	19981103	US 1997-852809	19970507
WO 9850550	A1	19981112	WO 1998-US9095	19980506
W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9873688	A1	19981127	AU 1998-73688	19980506
PRAI US 1997-852809		19970507		
WO 1998-US9095		19980506		

AB The present invention provides a human translocation assocd. protein (Gp25L-H) and polynucleotides which identify and encode Gp25L-H. Nucleic acid encoding human Gp25L-H was first identified in Incyte clone 1858818

SEARCHED BY SUSAN HANLEY 305-4053

from a tumor-assocd. **prostate** cDNA library through a computer search for amino acid sequence alignments; a consensus sequence was derived from overlapping and/or extended nucleic acid sequences. Gp25L-H is 218 amino acids in length, has a potential N-linked glycosylation site at position 106, and has chem. and structural homol. with human gp25L2, canine gp25L, and Xenopus TRAP-like protein. Northern anal. shows the expression of Gp25L-H in libraries prepd. from secretory glands, parts of the gastrointestinal tract, neuronal tissues, cardiovascular tissues, and tissues assocd. with inflammation and the immune response. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases assocd. with expression of Gp25L-H, as well as diagnostic assays.

L8 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2000 ACS

AN 1998:550509 HCAPLUS

DN 129:185078

TI A human homolog of the Caenorhabditis dosage compensation-associated protein DPY-30 identified by gene discovery

IN Lal, Preeti; Goli, Surya K.

PA Incyte Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835038	A1	19980813	WO 1998-US2161	19980205
	W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5955302	A	19990921	US 1997-795444	19970206
	AU 9861450	A1	19980826	AU 1998-61450	19980205
PRAI	US 1997-795444		19970206		
	WO 1998-US2161		19980205		

AB A cDNA for a human dosage compensation-assocd. protein (HDCAP) homologous to the DPY-30 protein of Caenorhabditis elegans is identified by gene discovery. A randomly picked clone from a human **prostate** library was found to show homol. to the gene for DPY-30.

L8 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2000 ACS

AN 1998:221135 HCAPLUS

DN 128:266948

TI Methods for generating and analyzing transcript markers from 5'- and 3'-ends of cDNAs

IN Wang, Bruce B.; Chung, Alicia; Guegler, Karl J.; Yang, Zhi;

Cocks, Benjamin Graeme; Stuart, Susan G.

PA Incyte Pharmaceuticals, Inc., USA; Wang, Bruce B.; Chung, Alicia; Guegler, Karl J.; Yang, Zhi; Cocks, Benjamin Graeme; Stuart, Susan G.

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9814619	A1	19980409	WO 1997-US18344	19971003
	W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9747533	A1	19980424	AU 1997-47533	19971003
PRAI	US 1996-723646		19961003		
	WO 1997-US18344		19971003		

AB A method of generating transcript markers for use in rapid, high-throughput gene discovery methods is described. The method can be used to create 5'-markers or sep. 5'- and 3'-markers. The present

SEARCHED BY SUSAN HANLEY 305-4053

invention provides methods and vectors useful for constructing libraries of transcript markers. These markers are generated by cleaving the cDNA with a combination of type II and type IIs restriction enzymes to release a sequence that can be cloned and characterized for use as a marker. A no. of variants of the basic idea are also described.

=&gt; D BIB ABS L14 1-2

## L14 ANSWER 1 OF 2 USPATFULL

AN 1999:155481 USPATFULL  
 TI Polynucleotide encoding human G-protein coupled receptor  
 IN **Lal, Preeti**, Santa Clara, CA, United States  
**Guegler, Karl J.**, Menlo Park, CA, United States  
 Shah, Purvi, Sunnyvale, CA, United States  
**Corley, Neil C.**, Mountain View, CA, United States  
 PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)  
 PI US 5994097 19991130  
 AI US 1997-919624 19970828 (8)  
 DT Utility  
 EXNAM Primary Examiner: Mertz, Prema  
 LREP Incyte Pharmaceuticals Inc.  
 CLMN Number of Claims: 7  
 ECL Exemplary Claim: 1  
 DRWN 14 Drawing Figure(s); 14 Drawing Page(s)  
 LN.CNT 2384

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a human G-protein coupled receptor (GReCH) and polynucleotides which identify and encode GReCH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GReCH.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

## L14 ANSWER 2 OF 2 USPATFULL

AN 1999:150964 USPATFULL  
 TI Human ion transport-like protein  
 IN **Lal, Preeti**, Santa Clara, CA, United States  
**Corley, Neil C.**, Mountain View, CA, United States  
**Guegler, Karl J.**, Menlo Park, CA, United States  
 Patterson, Chandra, Mountain View, CA, United States  
 PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)  
 PI US 5989861 19991123  
 AI US 1998-121179 19980722 (9)  
 DT Utility  
 EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Basi, Nirmal S.  
 LREP Incyte Pharmaceuticals, Inc.  
 CLMN Number of Claims: 7  
 ECL Exemplary Claim: 1  
 DRWN 2 Drawing Figure(s); 3 Drawing Page(s)  
 LN.CNT 2398

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a human ion transport-like protein (HITLP) and polynucleotides which identify and encode HITLP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HITLP.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=&gt;